Episodic Migraine

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy, Safety, and Tolerability of Subcutaneous Administration of Framanezumab Versus Placebo for the Preventative Treatment of Episodic Migraine in Pediatric Patients 6 to 17 Years of Age